Two novel mutations in glucocerebrosidase, C23W and IVS7 - 1 G > A, identified in Type 1 Gaucher patients heterozygous for N370S

被引:4
作者
Jack, Alexandria [1 ]
Amato, Dominick [2 ,3 ]
Morris, Geoffrey [1 ]
Choy, Francis Y. M. [1 ]
机构
[1] Univ Victoria, Dept Biol, Biomed Res Ctr, Victoria, BC V8W 3N5, Canada
[2] Mt Sinai Hosp, Mark Freedman & Judy Jacobs Program Gaucher Dis, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Toronto, ON, Canada
关键词
Gaucher disease; Sphingolipidosis; Novel mutations; Null allele; Compound heterozygosity; RFLP analysis; ACID-BETA-GLUCOSIDASE; DISEASE; GENE; FEATURES;
D O I
10.1016/j.gene.2014.01.015
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Gaucher disease is an autosomal recessive lysosomal storage disorder resulting from deficient glucocerebrosidase activity. There have been nearly 300 mutations described to date. Novel mutations can potentially provide insight into the biochemical basis of the disease. Two novel mutations are described in two Type 1 Gaucher patients with N370S compound heterozygosity; a point mutation that causes an amino acid substitution at cysteine residue 23 for nyptophan, and a second point mutation within the splicing element at the 3' end of intron 7. Both mutations were identified by PCR amplification and sequence analysis of patient glucocerebrosidase genomic DNA. Restriction fragment length polymorphism analysis was established for both novel mutations for efficient identification in future patients. Past literature suggests that mutations affecting cysteine residues involved in disulfide bridges, as well as mutations affecting splicing patterns of the glucocerebrosidase transcript, are detrimental to enzyme activity. However, compound heterozygosity with N370S, a mild mutation, will lead to a mild phenotype. The cases reported here support these past findings. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:84 / 87
页数:4
相关论文
共 25 条
[1]   Splicing in action: assessing disease causing sequence changes [J].
Baralle, D ;
Baralle, M .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (10) :737-748
[2]  
Beutler E, 1996, HUM MUTAT, V8, P207, DOI 10.1002/(SICI)1098-1004(1996)8:3<207::AID-HUMU2>3.3.CO
[3]  
2-5
[4]  
BEUTLER E, 1992, BLOOD, V79, P1662
[5]  
Beutler E., 1995, The Metabolic Basis of Inherited Disease, P2641
[6]   Variant Gaucher disease characterized by dysmorphic features, absence of cardiovascular involvement, laryngospasm, and compound heterozygosity for a novel mutation (D409H/C16S) [J].
Bodamer, OAF ;
Church, HJ ;
Cooper, A ;
Wraith, JE ;
Scott, CR ;
Scaglia, F .
AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 109 (04) :328-331
[7]   METABOLISM OF GLUCOCEREBROSIDES .2. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHERS DISEASE [J].
BRADY, RO ;
KANFER, JN ;
SHAPIRO, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1965, 18 (02) :221-&
[8]  
Choy FYM, 1997, AM J MED GENET, V71, P172, DOI 10.1002/(SICI)1096-8628(19970808)71:2<172::AID-AJMG10>3.0.CO
[9]  
2-B
[10]   Homozygous loss of a cysteine residue in the glucocerebrosidase gene results in Gaucher's disease with a hydropic phenotype [J].
Church, HJ ;
Cooper, A ;
Stewart, F ;
Thornton, CM ;
Wraith, JE .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2004, 12 (11) :975-978